Wedbush Reiterates Outperform on Aktis Oncology, Maintains $35 Price Target

Benzinga Newsdesk www.benzinga.com Negative 52.2%

Neg 52.2% Neu 0% Pos 0%

Wedbush analyst David Nierengarten reiterates Aktis Oncology (NASDAQ:AKTS) with a Outperform and maintains $35 price target.